Brigimadlin

Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.

Brigimadlin (BI 907828) is an oral MDM2-p53 antagonist showing potential in treating dedifferentiated liposarcoma (DDLPS) by restoring normal p53 activity.

Boehringer Ingelheim has reported significant progress in its pharmaceutical pipeline during the first half of 2024, with notable advancements in cardiovascular, renal, metabolic health, and oncology. The company also experienced a 7.4% year-on-year growth in net sales, driven by high demand for its medications. Key developments include positive Phase II data for survodutide in treating metabolic dysfunction-associated steatohepatitis (MASH) and the initiation of a Phase III trial for a novel selective aldosterone synthase inhibitor in chronic heart failure.

Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, cardiovascular, renal, and metabolic diseases.